CN1777673B - IgA1沉积疾病的治疗 - Google Patents

IgA1沉积疾病的治疗 Download PDF

Info

Publication number
CN1777673B
CN1777673B CN2004800062159A CN200480006215A CN1777673B CN 1777673 B CN1777673 B CN 1777673B CN 2004800062159 A CN2004800062159 A CN 2004800062159A CN 200480006215 A CN200480006215 A CN 200480006215A CN 1777673 B CN1777673 B CN 1777673B
Authority
CN
China
Prior art keywords
iga1
asn
thr
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800062159A
Other languages
English (en)
Chinese (zh)
Other versions
CN1777673A (zh
Inventor
安德鲁·G·普劳特
仇家舟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Publication of CN1777673A publication Critical patent/CN1777673A/zh
Application granted granted Critical
Publication of CN1777673B publication Critical patent/CN1777673B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CN2004800062159A 2003-03-07 2004-03-05 IgA1沉积疾病的治疗 Expired - Lifetime CN1777673B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45305503P 2003-03-07 2003-03-07
US60/453,055 2003-03-07
PCT/US2004/006615 WO2004096157A2 (en) 2003-03-07 2004-03-05 Treatment of igai deposition diseases

Publications (2)

Publication Number Publication Date
CN1777673A CN1777673A (zh) 2006-05-24
CN1777673B true CN1777673B (zh) 2010-04-28

Family

ID=33418058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800062159A Expired - Lifetime CN1777673B (zh) 2003-03-07 2004-03-05 IgA1沉积疾病的治疗

Country Status (10)

Country Link
US (3) US7407653B2 (enExample)
EP (1) EP1603511B1 (enExample)
JP (4) JP5438886B2 (enExample)
KR (2) KR20130026513A (enExample)
CN (1) CN1777673B (enExample)
AT (1) ATE496992T1 (enExample)
CA (1) CA2558873C (enExample)
DE (1) DE602004031199D1 (enExample)
ES (1) ES2360291T3 (enExample)
WO (1) WO2004096157A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130026513A (ko) 2003-03-07 2013-03-13 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 ＩｇＡ1 침착 질환 치료
US8440191B2 (en) 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
US20100261252A1 (en) * 2009-04-10 2010-10-14 Biomarin Pharmaceutical Inc. Methods of enhancing yield of active iga protease
WO2010123885A2 (en) * 2009-04-20 2010-10-28 Tufts Medical Center, Inc. Iga1 protease polypeptide agents and uses thereof
CN104073474A (zh) * 2014-06-27 2014-10-01 樊均明 一种IgA1酶及其制备方法和应用
US20170369551A1 (en) * 2016-06-24 2017-12-28 Anthera Pharmaceuticals, Inc. METHODS OF TREATING IgA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA NEPHRITIS USING A B-CELL ACTIVATING FACTOR (BAFF) INHIBITOR
CN115197328B (zh) * 2021-04-09 2025-05-16 北京大学第一医院 一种可清除体内免疫球蛋白A的重组融合蛋白酶及其制备方法和在治疗IgA肾病中的应用
US20250242002A1 (en) * 2022-01-29 2025-07-31 Peking University First Hospital Truncated forms of iga protease, fusion proteins comprising a truncated form of iga protease and uses thereof
KR20250114034A (ko) 2022-11-11 2025-07-28 아이간 바이오사이언스 Iga 프로테아제 폴리펩타이드 제제
WO2025183146A1 (ja) * 2024-02-29 2025-09-04 積水メディカル株式会社 免疫学的測定方法、免疫学的測定用試薬、免疫学的測定用検体前処理液、免疫学的測定用試薬キット、及び非特異反応抑制剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DK130889A (da) * 1989-03-17 1990-09-18 Mogens Kilian Immunoglobulin a1-proteaser (iga1-proteaser), fremgangsmaade til genteknologisk fremstilling af saadanne enzymer samt vaccine indeholdende enzymerne og fragmenter deraf til immunisering mod bakteriel meningitis og andre sygdomme fremkaldt af iga1-protease-producerende bakterier
ATE396399T1 (de) * 1998-03-31 2008-06-15 Asahi Kasei Pharma Corp Verfahren zur untersuchung der iga-nephropathie
DK2067788T3 (da) 1999-05-18 2015-10-19 Dyax Corp Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf
KR20130026513A (ko) * 2003-03-07 2013-03-13 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 ＩｇＡ1 침착 질환 치료

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
登录号X59800.EMBL数据库.1999, *

Also Published As

Publication number Publication date
US20090041746A1 (en) 2009-02-12
JP2015096079A (ja) 2015-05-21
US20090130084A1 (en) 2009-05-21
WO2004096157A3 (en) 2005-10-20
EP1603511A4 (en) 2007-06-06
US8216568B2 (en) 2012-07-10
US7407653B2 (en) 2008-08-05
EP1603511A2 (en) 2005-12-14
CN1777673A (zh) 2006-05-24
ES2360291T3 (es) 2011-06-02
HK1090950A1 (zh) 2007-01-05
JP2013230157A (ja) 2013-11-14
EP1603511B1 (en) 2011-01-26
ATE496992T1 (de) 2011-02-15
CA2558873C (en) 2015-10-20
KR20060015468A (ko) 2006-02-17
WO2004096157A2 (en) 2004-11-11
DE602004031199D1 (de) 2011-03-10
KR20130026513A (ko) 2013-03-13
CA2558873A1 (en) 2004-11-11
US20050136062A1 (en) 2005-06-23
JP5438886B2 (ja) 2014-03-12
JP2011101645A (ja) 2011-05-26
JP2006519619A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
US8216568B2 (en) Combination therapy with IgA1 proteases
Vipond et al. Defined deletion mutants demonstrate that the major secreted toxins are not essential for the virulence of Aeromonas salmonicida
CN1679929B (zh) 链球菌C5a肽酶疫苗
ES2904884T3 (es) Enzima del clostridium histolyticum
CN111499725A (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
JPS61500646A (ja) ファクタ−８および関連生産物の製造
Zhao et al. Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection
TW200817517A (en) Protease screening methods and proteases identified thereby
Lee et al. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii
Lin et al. Analysis of capsid portal protein and terminase functional domains: interaction sites required for DNA packaging in bacteriophage T4
Ciborowski et al. Staphylococcal enzymes and virulence
US11236315B2 (en) Thermophile peptidoglycan hydrolase fusion proteins and uses thereof
Shiryaev et al. Structural and functional diversity of metalloproteinases encoded by the Bacteroides fragilis pathogenicity island
AU714435B2 (en) Methods and compositions for identifying streptococcus containing a cysteine protease or fragment thereof
CN101412994B (zh) 使用粒酶b蛋白酶切割融合蛋白
Rigolet et al. The structural basis for catalysis and specificity of the X-prolyl dipeptidyl aminopeptidase from Lactococcus lactis
CA3195929A1 (en) Compositions and methods for treating celiac sprue disease
KR20110086711A (ko) 봉입체 형성 단백질의 제조방법
MXPA06001393A (es) Proteasa especifica de ubiquitina.
Kassab Bacterial Thrombolytic Enzyme Synthesis and Screening from Several Egyptian Soil Conditions
Gaur et al. Role of aspartic acid 121 in human pancreatic ribonuclease catalysis
JP2025537294A (ja) ＩｇＡプロテアーゼポリペプチド剤
HK40034619A (en) Tear lipocalin muteins binding il-4 r alpha
HK1090950B (en) Treatment of iga1 deposition diseases
Julius Protein Processing and Secretion in Yeast: Biosynthesis of Alpha-Factor Mating Pheromone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1090950

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1090950

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20100428

CX01 Expiry of patent term